Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ariad Pharmaceuticals, Inc. : ARIAD Announces Completion of Public Offering

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/29/2013 | 10:20pm CET

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of its previously announced public offering of 15,307,000 shares of common stock at a public offering price of $19.60 per share. In addition, the underwriters have exercised an option to purchase an additional 1,182,893 shares at $19.60 per share to cover over-allotments. The total gross proceeds from the offering are approximately $323 million. Net proceeds to ARIAD are approximately $310 million after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company, Inc. acted as joint book-running managers and underwriters for the offering. BMO Capital Markets, Leerink Swann LLC, RBC Capital Markets, LLC and UBS Investment Bank acted as co-managers for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204), the offices of Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 631-274-2806), or the offices of Jefferies & Company, Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ARIAD

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. For more information about ARIAD, visit the company's website at www.ariad.com.

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
12/07 ARIAD PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial..
12/07 ARIAD PHARMACEUTICALS : ARIADs Investigational Medicine Brigatinib Demonstrated ..
12/07 ARIAD PHARMACEUTICALS : Investigational Medicine Brigatinib Demonstrated 15.6 Mo..
12/06 ARIAD PHARMACEUTICALS : Announces Data Presentations at American Society of Hema..
12/05 ARIAD PHARMACEUTICALS : Presents Updated Brigatinib Data with 18.4 Months Median..
12/02 ARIAD PHARMACEUTICALS : to Host Webcast and Conference Call on Brigatinib Data P..
12/02 BEST BIOTECH STOCKS 2016 : The NASDAQ’s Top-Performers
11/30 ARIAD PHARMACEUTICALS, INC. (N : ARIA) Files An 8-K Other Events
11/30 ARIAD PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (for..
11/29 ARIAD PHARMACEUTICALS : Announces FDA Full Approval and Label Update for Iclusig..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/07 ARIAD's brigatinib stops lung cancer progression for almost 16 months in mid-..
12/05 ARIAD : The Storm Has Passed
11/29 FDA fully approves ARIAD's Iclusig and a label update to include four-year fo..
11/29 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
11/29 Small Caps Biggest Winners
Advertisement
Financials ($)
Sales 2016 196 M
EBIT 2016 -112 M
Net income 2016 -7,71 M
Debt 2016 152 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 13,4x
EV / Sales 2017 11,3x
Capitalization 2 478 M
More Financials
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Technical analysis trends ARIAD PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 13,1 $
Spread / Average Target 2,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paris Panayiotopoulos President, Chief Executive Officer & Director
Alexander John Denner Chairman
Manmeet Singh Soni Chief Financial Officer, Treasurer & Executive VP
Timothy P. Clackson Chief Scientific Officer
Nicholas Ventresca Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS,..104.16%2 478
AMGEN, INC.-13.02%105 034
GILEAD SCIENCES, INC.-28.08%95 884
CELGENE CORPORATION-5.93%87 334
REGENERON PHARMACEUTIC..-33.32%38 181
ACTELION LTD45.20%22 191
More Results